Presentation is loading. Please wait.

Presentation is loading. Please wait.

Addex Pharmaceuticals Investor Presentation July 2010.

Similar presentations

Presentation on theme: "Addex Pharmaceuticals Investor Presentation July 2010."— Presentation transcript:

1 Addex Pharmaceuticals Investor Presentation July 2010

2 Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments. These materials are strictly confidential and must not be disclosed or distributed to third parties.

3 3 Goal: allosteric modulators for human health Focus: CNS, metabolic disorders, inflammation Proprietary allosteric modulator discovery platform 15 discovery/development programs Pharma validation – Partners: Johnson & Johnson and Merck & Co., Inc. – Investors: SR-One (GSK) and Roche Venture Fund 138 staff / founded 2002 in Geneva, Switzerland The Company

4 4 Financials Cash for operations through end of 2011  CHF76.6 million (€52m/US$71m) at end of 2009 Market cap (8 July): CHF55.6m (€41.6m / US$52.6m) SIX Swiss Exchange: ADXN (ISIN:CH0029850754) 5,871,242 shares outstanding as of Dec 31, 2009 Five analysts covering: Piper JaffraySam Fazeli & Michael Aitkenhead JefferiesPeter Welford & Philippa Gardner HelveaOlav Zilian Bank VontobelAndrew C. Weiss & Silvia Schanz Bank am BellevueBob Pooler

5 PartnerPhase IIPreclinicalPhase IMilestone Lead Optimization Hit-to-Lead Assay Development & Screening Molecule / Mechanism PIPELINE Merck & Co., Inc. Ortho-McNeil-Janssen ADX68692 FSHR NAM ADX63365 mGluR5 PAM ADX71943 GABA-B PAM ADX71149 mGluR2 PAM Start Ph IIa 2H10 Start Ph II 4Q10 Start Ph IIa 1Q11 Ortho-McNeil-Janssen Start Ph IIa 2H10 ADX48621 mGluR5 NAM NAM = negative allosteric modulator (an inhibitor) ‡ and undisclosed additional indications PAM = positive allosteric modulator (an activator) * Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson subsidiary Parkinson’s Disease Levodopa Induced Dyskinesia (PD-LID) Dystonia Schizophrenia Anxiety Osteoarthritic Pain Schizophrenia ‡ Endometriosis / Benign Prostatic Hyperplasia funded & developed by OMJPI* funded & developed by Merck

6 PartnerPhase IIPreclinicalPhase IMilestone Lead Optimization Hit-to-Lead Assay Development & Screening Molecule / Mechanism DISCOVERY PROGRAMS NAM = negative allosteric modulator (an inhibitor) ‡ and undisclosed additional indications PAM = positive allosteric modulator (an activator) Inflammation CNS Metabolic Disorders Merck & Co., Inc. Alzheimer’s / Depression Parkinson’s Disease ‡ Depression Post Traumatic Stress Disorder Sleep Disorders Type II Diabetes Rheumatoid Arthritis, Psoriasis, Alzheimer’s, Multiple Sclerosis Psoriasis, Osteoarthritis Gout, Type II Diabetes funded by Merck mGluR4 PAM GIPR PAM TNFR1 NAM (CD120a) GLP1 PAM Orexin 2R NAM mGluR7 NAM mGluR2 NAM A2A PAM IL1R1 NAM (CD121a)

7 7 R&D Day 2010 Highlights ADX48621 to start Phase II testing in 2010 in PD-LID & dystonia ADX71149 to start Phase IIa in 2010 in schizophrenia & anxiety  previously undisclosed deal terms revealed Oral mGluR4 PAM (partnered with Merck & Co., Inc.) reduced anxiety in a preclin model Oral GLP-1 receptor (GLP1R) PAM preclinical proof of concept: When administered to “db/db” mice (model of Type II diabetes) being given glucose we observed  significantly enhanced insulin secretion  significantly reduced the rise in plasma glucose Addex identified as an IL1R NAM a clinically validated anti-inflammatory molecule, which had not previously been identified as an IL1R antagonist.

8 8 Partnered Programs

9 9 Agreement With Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) – Utilize Addex platform to identify & develop orally available mGluR2 PAM for schizophrenia, anxiety and undisclosed indications OMJPI funds collaboration on discovery & lead optimization OMJPI funds & performs preclinical and clinical development – Addex sits on oversight committees ADX71149 Terms €3 million upfront Research funding to Addex during discovery collaboration (2005-2007) €112 in potential milestones upon completion of clinical and regulatory milestones Low double-digit royalties

10 10 Progress to Date Collaboration generated clinical candidates – €4.2 million in R&D funding between 2005-2007 Comprehensive Ph I program started in June 2009 – €1 million milestone paid upon initiation of Phase I – More than 5 Phase I trials in healthy volunteers SAD, MAD Food & gender Ketamine challenge (schizophrenia model) Anxiety challenge Phase II program scheduled to start in 2010 – schizophrenia – anxiety – potentially other indications Note mGluR2 activation is clinically validated in anxiety & schizophrenia ADX71149 * Nature Medicine 2007:

11 11 ADX63365 Agreement Merck & Co., Inc. licensed Addex mGluR5 PAMs in 2008 mGluR5 PAM expected to be highly differentiated – Merck already had demonstrated mGluR5 PAM have efficacy in animal models of schizophrenia – Preclinical data show efficacy for cognitive deficit (& psychosis) – Despite efficacy of marketed drugs many schizophrenia patients remain unable to learn new skills to support themselves – FDA has recognized cognitive deficit as an unmet medical need in schizophrenia Merck is responsible for development of ADX63365 & backups Terms $22 million upfront $680 million in milestones Undisclosed royalties

12 12 Progress Deal signed (Dec 07) 1 st Preclinical milestone (Feb 08) – $250,000 2 nd preclinical milestone (Jul 09) – $500,000 – Orally available mGluR4 PAM showed efficacy in model of PD Collaboration extended (Dec 09) – Merck commits $1.8 million in research funding – Going forward all costs transferred to Merck Agreement Discover and develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAM) with Merck & Co., Inc. The deal includes mGluR4 PAM leads already discovered by Addex Merck is responsible for preclinical and clinical development Addex will sit on oversight committees Terms $3 million upfront $167.5 million in potential milestones Annual tech access fee $250,000 Research funding 2009/2010 Undisclosed royalties Option to co-promote in EU mGluR4 PAM

13 13 Platform Revenues Partner ProductIndication(s) Status at signing Status April 30, 2010 Upfront Cash Milestones or R&D funding received Total Potential Milestones Ortho-McNeil-Janssen Pharmaceuticals, Inc. mGluR2 PAM ADX71149 Anxiety & schizophrenia Hit-to-Lead (Dec 2004) Phase I€3 million€5.2 million€112 million Merck & Co., Inc.mGluR4 PAM Parkinson’s disease Hit-to-Lead (Dec 2007) preclinical efficacy in PD model $3 million$2.5 million$167.5 million Merck & Co., Inc. mGluR5 PAM ADX63365 schizophrenia Clinical Candidate (Jan 2008) not disclosed $22 millionn.a.$680 million Proprietary PlatformRevenues Addex has received partnering revenue every year since 2004 Cash inflows generated to date: CHF43 million All three partnerships are fully funded by our partners Potential for up to about $1 billion in milestones plus royalties * and undisclosed indications

14 14 Wholly Owned Programs

15 15 ADX48621 Overview Phase I completed – Three studies: SAD, MAD, gender & food effects – 110 patients treated to date, including older volunteers – Safety & tolerability justify further clinical study Differentiated – Only product shown to reduce dystonia in MPTP model – Chemical series unrelated to other mGluR5 NAM Unique metabolic profile – NCE patents valid through 2025 in most territories – Unrelated series of backup molecules in clinical candidate selection

16 16 ADX48621 effects in HIC model suggest It should be tested further as a potential drug for PD It has potential to be a dopamine sparing agent ADX48621 efficacy in HIC model Haloperidol induced catalepsy (HIC) is a preclinical model of PD ADX48621 dose-dependently reversed HIC in 3 independent experiments MTEP mGluR5 antagonist is well documented to work in the HIC model **p<0.01, ***p<0.001 versus vehicle group

17 17 MPTP model of PD-LID What is the MPTP Model? MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) – Neurotoxin destroys dopaminergic neurons – Symptoms similar to PD, treatable with levodopa MPTP monkeys develop levodopa induced dyskinesia (LID), including both chorea (trembling) and dystonia (cramping) seen in humans MPTP PD-LID model is predictive of efficacy in humans – KOLs consider it among the most translational models in the CNS space – AFQ056 (mGluR5/Novartis) showed efficacy in MPTP PD-LID model – AFQ056 showed efficacy in Phase IIa PD-LID trial

18 18 ADX48621 or vehicle administered 30 min prior to levodopa Behavioral assessment began upon levodopa administration – trained observers performed video review – dyskinesia & PD disability scoring (10 min every 30 min for 2hrs)  lower scores (left axis) indicate fewer symptoms/disability  dyskinesia symptoms are side effects from levodopa  disability is a measure of Parkinson’s disease severity ADX48621 MPTP Study Design

19 19 ADX48621 reduced dyskinesia without compromising levodopa efficacy ADX48621 dose-dependently reduced dyskinesia (chorea + dystonia) Dyskinesia ADX48621 efficacy in MPTP model ADX48621 does not reduce levodopa efficacy Disability + levodopa

20 20 ADX48621 is the first drug-candidate known to have efficacy on dystonia Dystonia Dystonia = sustained muscle contractions (e.g. cramps) Chorea Chorea = involuntary movements (e.g. trembling) ADX48621 efficacy in MPTP model

21 21 ADX48621development plan PD-LID: Study ADX48621-201 – U.S. & EU Phase II trial in about 140 PD-LID patients – Double-blind, placebo-controlled, two doses of ADX48621 – 6 weeks treatment – Endpoints: multiple instruments (in consultation with KOLs) – Start 4Q2010 – Report data end 2011 or early 2012 Dystonia: Study ADX48621-202 – EU Phase IIa trial in about 32 dystonia patients – Double-blind, placebo-controlled, two-way crossover (two dose groups) – 2 week treatment period – Endpoints: multiple instruments (in consultation with KOLs) – Start 4Q2010 – Report data end 2011 or early 2012

22 22 ADX48621Commercial Potential Levodopa induced dyskinesia (LID) and dystonia are an unmet medical needs – Most Parkinson’s disease (PD) patients develop LID – no drugs specifically approved for PD-LID – growing unmet medical need – PD-LID/dystonia is a faster path to market than PD Addex can retain co-promotion rights – treated by specialists – geographic split possible – mGluR4 PAM & mGluR2 NAM represent potential additions to future neurodegenerative disease franchise

23 23 ADX71943 ADX71943 is a gamma-aminobutyric acid subtype B (GABA B )receptor PAM – Clinically/commercially validated mechanism generic GABA B agonist, baclofen, is marketed other orthosteric GABA B agonists are clinically validated – ADX71943 is differentiated ADX71943 is the only allosteric modulator of GABA B in development Demonstrated analgesic effects in three preclinical pain models Potential for chronic pain (e.g. osteoarthritis) and other indications Phase I to start 4Q10 ADX71943 is available for partnering

24 24 ADX68692 Roles of FSH/LH Females FSH involved in folliculogenesis – maturation of follicles – estrogen production LH triggers ovulation, progesterone Males FSH supports spermatogenesis LH stimulates testosterone production Status ADX68692 is a follicle stimulating hormone receptor (FSHR) NAM Orally available non-steroidal molecule with drug-like characteristics In late preclinical development ADX68692 is available for partnering Preclinical Data & Potential Indications Statistically significant reduction in testosterone & prostate weight  Benign prostatic hyperplasia (BPH) Statistically significant reduction in estradiol  Endometriosis

25 25 GLP-1 PAM project To develop a small molecule GLP-1 PAM for the treatment of Type II Diabetes –Orally available –Should increase insulin secretion and decrease blood glucose –No or reduced nausea/vomiting compared to competition –Should preferably induce weight loss –Could be used in combination with other therapies

26 26 Oral GLP1R PAM in db/db mouse model Leptin receptor–deficient db/db knockout mice are considered an established model –develop human Type II diabetes mellitus –hypertension and obesity –disrupted circadian blood pressure (BP) rhythm We orally administered to db/db mice –ADX91886 GLP1R PAM –Januvia sitagliptin DPP IV inhibitor –or vehicle 15 min later 2 g/kg glucose is given orally Blood glucose + insulin levels were measured 10 ; 20 ; 30 ; 60 ; 90 min after glucose administration

27 27 Oral GPL1R PAM compared to sitagliptin in db/db mice

28 28 Allosteric Modulator Discovery & Optimization

29 29 Allosteric Modulation Because they bind a different site on the receptor, allosteric modulators do not turn receptors on or off the way the body’s natural activators and most drugs do. Instead, they act more like a dimmer switch, offering control over the ease & intensity of (de-)activation while allowing the body to retain its natural control over initiating receptor activation via the active site (e.g. the on/off switch).

30 30 Allosteric Advantages Greater specificity than orthosteric molecules – e.g. mGluRs Can target receptors considered “intractable” or only tractable by biologics, peptides or proteins – e.g. GLP-1 Non-competitive mechanism – Un-exploited intellectual property – Less dose related toxicity Acts like a dimmer not “on/off” switch – Body maintains control of receptor activation cycle Natural ligand Time PAM + natural ligand NAM + natural ligand Biological response Allostery preserves natural rhythm Time Natural ligand Agonist Antagonist Biological response Orthosterics are steady state

31 31 Serendipity has yielded some marketed allosteric modulators. Most recent examples include: Sensipar/Mimpra cinacalcet (Amgen) – Positive allosteric modulator (PAM) of calcium sensing receptor – Approved 2004 – treats secondary hyperparathyroidism Selzentry/Celsentri maraviroc (Pfizer) – Negative allosteric modulator (NAM) of CCR5 – Approved 2007 – Treats CCR5-tropic HIV-1 Allosteric Modulators 101

32 32 Allosteric modulators are hard to find –Industrial tools for orthosteric drugs are not appropriate –Pharma has been focused on tools for finding orthosteric drugs –Why didn’t pharma industrialize allosteric drug discovery? Upfront investment to build allosteric drug discovery platform was high Time to value creation was long & uncertain Addex is industrializing allosteric modulation discovery –Proprietary assays High throughput screening & optimization tools (384 well plates & robotics) Direct detection systems –proximal to target –continuous real-time observation –works for molecules (i.e. allosteric modulators) that do not activate target receptor –Allostery biased library of over 70,000 compounds The Addex raison d'être

33 33 Proprietary Screening Assays G-Protein Coupled Receptors Phoenyx – a cAMP dynamic non stop assay FBBA (GLP1R, mGluR7) – Fluorescence-Based Binding Assay – Measures bi-molecular interactions Proxylite (GLP1R, GIP) – Proximal & dynamic assays for functional measurements of all types of GPCRs

34 34 APRA (TNFR1) – Accessory Protein Relocalization Assays ADX-tags series 1 (IL1R) – Proximal & dynamic assays for functional measurements – Measures activation-dependent association or dissociation of binding partners ADX-tags series 2 (TNFR1, IL1R) – measures conformational changes that lead to activation signal – measures multimerization changes that lead to activation signal Proprietary Screening Assays type 1 single-pass transmembrane proteins

35 35 Allostery Biased Library in-silico analysis Addex library and marketed drugs share the same physicochemical property space BUT Addex library occupies a unique structural space Physicochemical Comparison Structural Comparison Addex Compounds Marketed Drugs Addex Compounds Marketed Drugs

36 36 Platform Validation Addex identified selective orally available small molecules for –Challenging GPCRs (mGluRs, GABA-B & A2A) –Peptide receptors (GLP1R, GIPR) –Cytokine receptors (TNFR1 & IL1R1) The proof is in the pudding –Merck & Co., Inc. licensed mGluR4 PAM & mGluR5 PAM –Johnson & Johnson licensed mGluR2 PAM

37 37 Summary 15 Programs for High Value Targets/Indications – Highly differentiated allosteric mechanism – Low target related risk (i.e. mostly clinically validated targets) Allosteric Modulator Platform – Proprietary tools + tailored library – Platform + multi-disciplinary approach are scalable 3 Validating Partnerships (MRK/J&J) Top Tier Investors Cash to end of 2011

38 38 Management & Boards Vincent Mutel, Chief Executive Officer Tim Dyer, Chief Financial Officer Charlotte Keywood, Chief Medical Officer Sonia Poli, Head of Non-Clinical Development Laurent Galibert, Head of Inflammation & Metabolic Disorders Board of Directors André J. Mueller, Chairman Vincent Mutel, Vice Chairman & CEO of Addex Andrew Galazka, SVP Scientific Affairs, Merck-Serono Ray Hill, former Head of EU Licensing, Merck & Co., Inc. Vincent Lawton, former MD of Merck Sharp & Dohme U.K. Beat E. Lüthi, CEO of CTC Analytics Antoine Papiernik, Sofinnova Partners Scientific Advisory Board George F. Koob, Ph.D., Chairman Bernhard Bettler, Ph.D. Arthur Christopoulos, Ph.D. Patrick M. Sexton, Ph.D. Mark A. Geyer, Ph.D. Barbara J. Mason, Ph.D. Jean-Philippe Rocher, Head of Core Chemistry Robert Lütjens, Head of Core Biology Tatiana Carteret, Head of Human Resources Chris Maggos, Investor Relations & Communications Executive Management

39 39 allosteric modulators for human health

Download ppt "Addex Pharmaceuticals Investor Presentation July 2010."

Similar presentations

Ads by Google